Topical Formulation of Histone Deacetylase Inhibitors and Methods of Using the Same
Australia
2006283677
Filed on 2006-08-15
2006283677
Filed on 2006-08-15
Phenylacetate and Derivatives Alone or in Combination with Other Compounds Against Neoplastic Conditions and Other Disorders
Turkey
04030912.2
Filed on 1994-10-12
04030912.2
Filed on 1994-10-12
Phenylacetate and Derivatives Alone or in Combination with Other Compounds Against Neoplastic Conditions and Other Disorders
Slovakia
04030912.2
Filed on 1994-10-12
04030912.2
Filed on 1994-10-12
Phenylacetate and Derivatives Alone or in Combination with Other Compounds Against Neoplastic Conditions and Other Disorders
Slovenia
04030912.2
Filed on 1994-10-12
04030912.2
Filed on 1994-10-12
Phenylacetate and Derivatives Alone or in Combination with Other Compounds Against Neoplastic Conditions and Other Disorders
Sweden
04030912.2
Filed on 1994-10-12
04030912.2
Filed on 1994-10-12
Phenylacetate and Derivatives Alone or in Combination with Other Compounds Against Neoplastic Conditions and Other Disorders
Serbia
04030912.2
Filed on 1994-10-12
04030912.2
Filed on 1994-10-12
Phenylacetate and Derivatives Alone or in Combination with Other Compounds Against Neoplastic Conditions and Other Disorders
Romania
04030912.2
Filed on 1994-10-12
04030912.2
Filed on 1994-10-12
Phenylacetate and Derivatives Alone or in Combination with Other Compounds Against Neoplastic Conditions and Other Disorders
Portugal
04030912.2
Filed on 1994-10-12
04030912.2
Filed on 1994-10-12
Phenylacetate and Derivatives Alone or in Combination with Other Compounds Against Neoplastic Conditions and Other Disorders
Poland
04030912.2
Filed on 1994-10-12
04030912.2
Filed on 1994-10-12
Phenylacetate and Derivatives Alone or in Combination with Other Compounds Against Neoplastic Conditions and Other Disorders
The Netherlands
04030912.2
Filed on 1994-10-12
04030912.2
Filed on 1994-10-12